BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 35582230)

  • 1. Improving TRAIL-induced apoptosis in cancers by interfering with histone modifications.
    Zhang BJ; Chen D; Dekker FJ; Quax WJ
    Cancer Drug Resist; 2020; 3(4):791-803. PubMed ID: 35582230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of euchromatin histone-lysine N-methyltransferase 2 sensitizes breast cancer cells to tumor necrosis factor-related apoptosis-inducing ligand through reactive oxygen species-mediated activating transcription factor 4-C/EBP homologous protein-death receptor 5 pathway activation.
    Kim SY; Hong M; Heo SH; Park S; Kwon TK; Sung YH; Oh Y; Lee S; Yi GS; Kim I
    Mol Carcinog; 2018 Nov; 57(11):1492-1506. PubMed ID: 29964331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of TRAIL-induced apoptosis by HDAC inhibitors.
    Fulda S
    Curr Cancer Drug Targets; 2008 Mar; 8(2):132-40. PubMed ID: 18336196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitors strongly sensitise neuroblastoma cells to TRAIL-induced apoptosis by a caspases-dependent increase of the pro- to anti-apoptotic proteins ratio.
    Mühlethaler-Mottet A; Flahaut M; Bourloud KB; Auderset K; Meier R; Joseph JM; Gross N
    BMC Cancer; 2006 Aug; 6():214. PubMed ID: 16930472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone deacetylase (HDAC) inhibitors and regulation of TRAIL-induced apoptosis.
    Fulda S
    Exp Cell Res; 2012 Jul; 318(11):1208-12. PubMed ID: 22366288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long non-coding RNA HOTAIR enhances pancreatic cancer resistance to TNF-related apoptosis-inducing ligand.
    Yang SZ; Xu F; Zhou T; Zhao X; McDonald JM; Chen Y
    J Biol Chem; 2017 Jun; 292(25):10390-10397. PubMed ID: 28476883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
    Earel JK; VanOosten RL; Griffith TS
    Cancer Res; 2006 Jan; 66(1):499-507. PubMed ID: 16397266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylase inhibitors cooperate with IFN-gamma to restore caspase-8 expression and overcome TRAIL resistance in cancers with silencing of caspase-8.
    Häcker S; Dittrich A; Mohr A; Schweitzer T; Rutkowski S; Krauss J; Debatin KM; Fulda S
    Oncogene; 2009 Sep; 28(35):3097-110. PubMed ID: 19597472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors modulate renal cell carcinoma sensitivity to TRAIL/Apo-2L-induced apoptosis by enhancing TRAIL-R2 expression.
    VanOosten RL; Moore JM; Karacay B; Griffith TS
    Cancer Biol Ther; 2005 Oct; 4(10):1104-12. PubMed ID: 16096370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epigenetic silencing of apoptosis-inducing gene expression can be efficiently overcome by combined SAHA and TRAIL treatment in uterine sarcoma cells.
    Fröhlich LF; Mrakovcic M; Smole C; Lahiri P; Zatloukal K
    PLoS One; 2014; 9(3):e91558. PubMed ID: 24618889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy.
    Wang J; Wang H; Wang LY; Cai D; Duan Z; Zhang Y; Chen P; Zou JX; Xu J; Chen X; Kung HJ; Chen HW
    Cell Death Differ; 2016 Nov; 23(11):1886-1896. PubMed ID: 27612013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitors sensitize human colonic adenocarcinoma cell lines to TNF-related apoptosis inducing ligand-mediated apoptosis.
    Inoue H; Shiraki K; Ohmori S; Sakai T; Deguchi M; Yamanaka T; Okano H; Nakano T
    Int J Mol Med; 2002 May; 9(5):521-5. PubMed ID: 11956660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDAC inhibitors with different gene regulation activities depend on the mitochondrial pathway for the sensitization of leukemic T cells to TRAIL-induced apoptosis.
    Morales JC; Ruiz-Magaña MJ; Carranza D; Ortiz-Ferrón G; Ruiz-Ruiz C
    Cancer Lett; 2010 Nov; 297(1):91-100. PubMed ID: 20580868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of non-enzymatic glycosylation in the epigenetics of cancer.
    Rehman S; Aatif M; Rafi Z; Khan MY; Shahab U; Ahmad S; Farhan M
    Semin Cancer Biol; 2022 Aug; 83():543-555. PubMed ID: 33276090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Update of Epigenetic Drugs for the Treatment of Cancers and Brain Diseases: A Comprehensive Review.
    Sahafnejad Z; Ramazi S; Allahverdi A
    Genes (Basel); 2023 Apr; 14(4):. PubMed ID: 37107631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenomics in stress tolerance of plants under the climate change.
    Kumar M; Rani K
    Mol Biol Rep; 2023 Jul; 50(7):6201-6216. PubMed ID: 37294468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KDM2B, an H3K36-specific demethylase, regulates apoptotic response of GBM cells to TRAIL.
    Kurt IC; Sur I; Kaya E; Cingoz A; Kazancioglu S; Kahya Z; Toparlak OD; Senbabaoglu F; Kaya Z; Ozyerli E; Karahüseyinoglu S; Lack NA; Gümüs ZH; Onder TT; Bagci-Onder T
    Cell Death Dis; 2017 Jun; 8(6):e2897. PubMed ID: 28661478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-cell epigenetics - Chromatin modification atlas unveiled by mass cytometry.
    Cheung P; Vallania F; Dvorak M; Chang SE; Schaffert S; Donato M; Rao AM; Mao R; Utz PJ; Khatri P; Kuo AJ
    Clin Immunol; 2018 Nov; 196():40-48. PubMed ID: 29960011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas.
    Elias A; Siegelin MD; Steinmüller A; von Deimling A; Lass U; Korn B; Mueller W
    Clin Cancer Res; 2009 Sep; 15(17):5457-65. PubMed ID: 19706813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Downmodulation of dimethyl transferase activity enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in prostate cancer cells.
    Festuccia C; Gravina GL; D'Alessandro AM; Millimaggi D; Di Rocco C; Dolo V; Ricevuto E; Vicentini C; Bologna M
    Int J Oncol; 2008 Aug; 33(2):381-8. PubMed ID: 18636160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.